Abstracts tagged "Sjӧgrens"

Abstract Number: 640 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome in Male Patients Presents with Higher Autoantibody Levels and More Extraglandular Manifestations
Jorge Ramírez^1,2, Marika Kvarnstrom^2,3 and Marie Wahren-Herlenius^1,2, ¹Department of Medicine, Karolinska Institutet, Solna, Sweden, ²Department of Medicine, Experimental Rheumatology Unit, Solna, Sweden, ³Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Primary Sjögren’s syndrome (pSS) and SLE are chronic autoimmune diseases that predominantly affect women, with a female:male ratio of approximately 9:1. SLE in men…
Abstract Number: 2930 • 2014 ACR/ARHP Annual Meeting
Precisely Quantified Fibrosis in Labial Salivary Glands Predicts Sjögren’s Syndrome Classification in a Multiple Regression Model
Kerry M. Leehan^1,2, Michael Brown¹, Courtney Montgomery¹, Astrid Rasmussen¹, David M. Lewis³, Lida Radfar⁴, Donald U. Stone⁵, Stephen Young³, R. Hal Scofield^1,6, Kathy L. Sivils^1,2 and A. Darise Farris^2,7, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Department of Endocrinology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Primary Sjögren's Syndrome (pSS) is a systemic, progressive autoimmune exocrinopathy that presents diagnostic challenges. Focal lymphocytic infiltrates in labial salivary gland (SG) biopsies, serum…
Abstract Number: L3 • 2014 ACR/ARHP Annual Meeting
Low Protein A20 Expression in Minor Salivary Glands Is Associated with Lymphoma Development in Primary Sjögren’s Syndrome
Svein Joar A. Johnsen¹, Einar Gudlaugsson², Ivar Skaland², Emiel Janssen², Malin V. Jonsson³, Lars Helgeland⁴, Ellen Berget⁵, Roland Jonsson⁶ and Roald Omdal¹, ¹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ²Stavanger University Hospital, Stavanger, Norway, ³Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ⁴Haukeland University Hospital, Bergen, Norway, ⁵University of Bergen, Bergen, Norway, ⁶Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: Patients with primary Sjogrens syndrome (pSS) have an increased risk of developing lymphomas, especially of the subtype mucosa-associated lymphoid tissue (MALT) lymphoma. Chronic antigen…
Abstract Number: 515 • 2013 ACR/ARHP Annual Meeting
Does Multiplex Flow Immunoassay Underdetect SSA and SSB Antibodies? An Evaluation Of The Sjogren’s International Collaborative Clinical Alliance (SICCA) Cohort
Alan N. Baer¹, Laura Gutierrez², Mara McAdams DeMarco³, Mi Y. Lam⁴, Livia Casciola-Rosen⁵, Stephen Shiboski⁶, Caroline Shiboski⁴ and Lindsey A. Criswell⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Center Tower Ste 5300, Johns Hopkins University, Baltimore, MD, ³Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴Orofacial Sciences, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶University of California, San Francisco, San Francisco, CA, ⁷Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA
Background/Purpose: Multiplex flow immunoassays (MFIA) are used by clinical laboratories to test for antibodies to extractable nuclear antigens. The use of blended Ro52 and…
Abstract Number: 516 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Seronegative Sjogren’s Syndrome: A Comparative Study From The Sjogren’s International Collaborative Clinical Alliance (SICCA) Cohort
Alan N. Baer¹, Laura Gutierrez², Mara McAdams DeMarco³, Mi Y. Lam⁴, Livia Casciola-Rosen⁵, Stephen Shiboski⁶, Caroline Shiboski⁴ and Lindsey A. Criswell⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Center Tower Ste 5300, Johns Hopkins University, Baltimore, MD, ³Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴Orofacial Sciences, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶University of California, San Francisco, San Francisco, CA, ⁷Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA
Background/Purpose: Individuals with primary Sjogren’s syndrome (SS) may lack systemic autoantibodies. When defined by the absence of anti-SSA and –SSB antibodies, the reported range…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].